Stay updated on Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.

Latest updates to the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedFallopian tube cancer was added to the Conditions list and a Genetic and Rare Diseases Information Center resource was linked in Resources. The page revision is updated to v3.4.2 from v3.4.1.SummaryDifference0.1%

- Check18 days agoChange DetectedRevision: v3.4.1 was added and Revision: v3.4.0 was removed, which are minor UI/version changes not affecting study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check32 days agoChange DetectedShow glossary was added; update-related items (Last Update Submitted that Met QC Criteria and Last Update Posted) are displayed, and the page revision updated to Revision: v3.4.0, while older labeling such as No FEAR Act data and the previous revision text were removed.SummaryDifference0.1%

- Check39 days agoChange DetectedThe page metadata now shows Revision: v3.3.4, replacing the previous Revision: v3.3.3.SummaryDifference0.0%

- Check46 days agoChange DetectedRecruitment status for NCT05445778 was updated to Completed on 2026-01-07, replacing the prior Recruiting status recorded in 2025.SummaryDifference0.5%

- Check67 days agoChange DetectedRecruitment locations have been expanded and reorganized across numerous regions and countries, with many new sites added and some existing sites removed. This changes where participants may enroll in the study.SummaryDifference4%

Stay in the know with updates to Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.